Amantadine in the treatment of Parkinson's disease and other movement disorders

  title={Amantadine in the treatment of Parkinson's disease and other movement disorders},
  author={Olivier Rascol and Margherita Fabbri and Werner Poewe},
  journal={The Lancet Neurology},
The Pharmacological Potential of Adenosine A2A Receptor Antagonists for Treating Parkinson’s Disease
The pharmacology of adenosine A2A receptor antagonists from the perspective of the treatment of both motor and non-motor symptoms of PD and their potential for disease modification are reviewed.
Prevention of L-Dopa-Induced Dyskinesias by MPEP Blockade of Metabotropic Glutamate Receptor 5 Is Associated with Reduced Inflammation in the Brain of Parkinsonian Monkeys
It is revealed that MPEP inhibition of glutamate activity reduced LID and levels of inflammatory markers and a strong positive correlation between dyskinesia scores and microglial markers in these regions.
Anticancer Activity of Amantadine and Evaluation of Its Interactions with Selected Cytostatics in Relation to Human Melanoma Cells
Clinical observations revealed a high incidence of malignant melanoma in patients with Parkinson’s disease and amantadine as an anti-Parkinson drug alleviates symptoms of Parkinson's disease and theoretically, it should have anti-melanoma properties.
Drug repositioning: Progress and challenges in drug discovery for various diseases
A Randomized, Double‐Blind, Controlled Phase II Study of Foliglurax in Parkinson's Disease
Agents targeting the metabotropic glutamate receptor 4 have emerged as a potentially attractive new class of drugs for the treatment of Parkinson's disease (PD).
Challenges in Discovering Drugs That Target the Protein–Protein Interactions of Disordered Proteins
The difficulties and limitations of strategies to discover drugs that target PPIs directly or indirectly are reviewed, taking as examples the disordered proteins involved in neurodegenerative diseases.
Implementation and Outcomes of a Movement Disorder Society‐Sponsored Peer Reviewing Education and Mentoring Program
This dedicated program helped participants gain competence and confidence in the peer review process and plan to continue the program while improving educational methods and assessments.
Adamantanes for the Treatment of Neurodegenerative Diseases in the Era of the COVID-19 Pandemic
Systematic reviews with meta-analysis confirm the efficacy of amantadine for the treatment of the motor signs of PD and for L-Dopa-induced dyskinesias and the efficacy in patients infected with COVID-19.
The use of amantadine in catatonia


Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease
It is suggested that amantadine given as adjuvant to levodopa can markedly improve motor response complications and support the view that hyperfunction of NMDA receptors contributes to the pathogenesis oflevodopa-associated motor complications.
Amantadine for levodopa-induced dyskinesias: a 1-year follow-up study.
The beneficial effects of amantadine on motor response complications are maintained for at least 1 year after treatment initiation, and motor complications occurring with the patients' regular oral levodopa regimen also remained improved according to the Unified Parkinson's Disease Rating Scale (UPDRS-IV).
Huntington’s disease: A randomized, controlled trial using the NMDA-antagonist amantadine
It is suggested that NMDA receptor supersensitivity may contribute to the clinical expression of choreiform dyskinesias in HD and that selective antagonists at that site can safely confer palliative benefit.
Reduction of parkinsonian signs in patients with Parkinson's disease by dopaminergic versus anticholinergic single‐dose challenges
It is concluded that dopaminergic substances are as effective as anticholinergics in patients with parkinsonian tremor and additionally improve other parkinsonia signs.
Withdrawing amantadine in dyskinetic patients with Parkinson disease
Wash-out of amantadine in dyskinetic patients with Parkinson disease and levodopa-induced dyskinesia significantly worsened LID, and exploratory outcomes suggested that amanadine might improve apathy and fatigue in such patients.
Intravenous amantadine improves levadopa‐induced dyskinesias: An acute double‐blind placebo‐controlled study
This study confirms the antidyskinetic effect of amantadine and strengthens the rationale for using antiglutamatergic drugs in the treatment of parkinsonian motor fluctuations.
Long‐term antidyskinetic efficacy of amantadine in Parkinson's disease
  • E. Wolf, K. Seppi, W. Poewe
  • Medicine, Psychology
    Movement disorders : official journal of the Movement Disorder Society
  • 2010
Findings argue for long‐term antidyskinetic efficacy of amantadine in PD patients with LID's.
Effect of memantine (NMDA antagonist) on Parkinson's disease: a double-blind crossover randomized study.
The results suggest that memantine may improve parkinsonian symptoms independently of dopaminergic drugs and, in contrast to recent findings with amantadine, it has no effect on drug-induced dyskinesias.
Glutamate receptor antagonists for neuroleptic malignant syndrome and akitetic hyperthermic Parkinsonian crisis
The use of NMDA receptor antagonists is advocated in these medical emergencies and their clinical efficacy is linked to the common pathophysiological pathway of increased excitatory aminoacid neurotransmitter activity in neuroleptic malignant syndrome, Parkinsonian crisis, and dopamine agonist withdrawal states.